Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 17 | 2024 | 1426 | 2.900 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2023 | 209 | 2.060 |
Why?
|
| Aromatase Inhibitors | 5 | 2023 | 15 | 1.990 |
Why?
|
| Nitriles | 7 | 2023 | 66 | 1.580 |
Why?
|
| Triazoles | 7 | 2023 | 85 | 1.520 |
Why?
|
| Estrogens | 7 | 2023 | 190 | 1.350 |
Why?
|
| Cell Line, Tumor | 19 | 2023 | 2128 | 1.060 |
Why?
|
| Pterocarpans | 5 | 2022 | 20 | 0.980 |
Why?
|
| Endocrine Disruptors | 3 | 2012 | 38 | 0.870 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 756 | 0.800 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 93 | 0.770 |
Why?
|
| MicroRNAs | 4 | 2013 | 386 | 0.760 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 781 | 0.750 |
Why?
|
| Estrogen Receptor alpha | 7 | 2015 | 105 | 0.560 |
Why?
|
| Proteomics | 2 | 2021 | 302 | 0.560 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 1300 | 0.540 |
Why?
|
| Sesquiterpenes | 2 | 2013 | 30 | 0.470 |
Why?
|
| Cell Movement | 2 | 2015 | 545 | 0.470 |
Why?
|
| Cell Proliferation | 8 | 2022 | 1149 | 0.440 |
Why?
|
| Sulfides | 2 | 2024 | 58 | 0.440 |
Why?
|
| Allyl Compounds | 2 | 2024 | 47 | 0.440 |
Why?
|
| DDT | 1 | 2012 | 15 | 0.430 |
Why?
|
| Mammary Neoplasms, Experimental | 4 | 2020 | 70 | 0.430 |
Why?
|
| Female | 19 | 2024 | 19873 | 0.410 |
Why?
|
| Humans | 27 | 2024 | 34853 | 0.400 |
Why?
|
| Phenols | 1 | 2012 | 76 | 0.400 |
Why?
|
| Disease | 1 | 2010 | 18 | 0.380 |
Why?
|
| Apoptosis | 3 | 2022 | 1317 | 0.370 |
Why?
|
| Signal Transduction | 6 | 2021 | 1802 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 133 | 0.330 |
Why?
|
| Aromatase | 4 | 2022 | 19 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 242 | 0.260 |
Why?
|
| Garlic | 1 | 2024 | 31 | 0.240 |
Why?
|
| Cyclin B1 | 1 | 2023 | 16 | 0.230 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 81 | 0.230 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 416 | 0.220 |
Why?
|
| Transcription, Genetic | 4 | 2014 | 550 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2023 | 122 | 0.220 |
Why?
|
| Mice | 8 | 2020 | 5668 | 0.220 |
Why?
|
| Estradiol | 5 | 2012 | 244 | 0.220 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 34 | 0.200 |
Why?
|
| Receptors, Estrogen | 5 | 2014 | 145 | 0.190 |
Why?
|
| Receptors, CXCR4 | 2 | 2011 | 67 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 229 | 0.190 |
Why?
|
| Breast | 1 | 2021 | 134 | 0.190 |
Why?
|
| Organ Culture Techniques | 1 | 2020 | 99 | 0.190 |
Why?
|
| Animals | 10 | 2020 | 14307 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 220 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 92 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 142 | 0.180 |
Why?
|
| Mice, Nude | 3 | 2015 | 323 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2020 | 1442 | 0.170 |
Why?
|
| Epithelial Cells | 1 | 2021 | 366 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 484 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 117 | 0.140 |
Why?
|
| Estrogen Antagonists | 3 | 2010 | 26 | 0.130 |
Why?
|
| Cell Division | 2 | 2014 | 296 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2014 | 36 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2013 | 834 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2010 | 31 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 2 | 2012 | 162 | 0.120 |
Why?
|
| Cell Shape | 1 | 2013 | 35 | 0.120 |
Why?
|
| Vimentin | 1 | 2013 | 32 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 30 | 0.120 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 30 | 0.120 |
Why?
|
| Chalcone | 1 | 2013 | 5 | 0.120 |
Why?
|
| Mesoderm | 1 | 2013 | 70 | 0.110 |
Why?
|
| Amides | 1 | 2013 | 66 | 0.110 |
Why?
|
| Pyridines | 1 | 2013 | 113 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 66 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 247 | 0.110 |
Why?
|
| Carcinoma | 1 | 2012 | 94 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 97 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 42 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 94 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 28 | 0.100 |
Why?
|
| Reproduction | 1 | 2011 | 63 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 107 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 203 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2010 | 16 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 968 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2015 | 653 | 0.100 |
Why?
|
| Receptors, Estradiol | 1 | 2010 | 2 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 37 | 0.090 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2009 | 18 | 0.090 |
Why?
|
| Terpenes | 1 | 2009 | 28 | 0.090 |
Why?
|
| Environmental Pollutants | 1 | 2011 | 166 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 65 | 0.090 |
Why?
|
| Flavonols | 1 | 2008 | 15 | 0.090 |
Why?
|
| Fermentation | 1 | 2008 | 25 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2009 | 54 | 0.090 |
Why?
|
| Phytoestrogens | 1 | 2008 | 35 | 0.090 |
Why?
|
| Mice, SCID | 3 | 2013 | 143 | 0.070 |
Why?
|
| Androgens | 1 | 2006 | 87 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2014 | 751 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 178 | 0.060 |
Why?
|
| DNA Polymerase beta | 1 | 2021 | 13 | 0.050 |
Why?
|
| Bromodeoxyuridine | 1 | 2021 | 22 | 0.050 |
Why?
|
| DNA Damage | 1 | 2024 | 341 | 0.050 |
Why?
|
| Antioxidants | 1 | 2024 | 386 | 0.050 |
Why?
|
| Benzo(a)pyrene | 1 | 2021 | 122 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2021 | 309 | 0.050 |
Why?
|
| Stereoisomerism | 2 | 2010 | 162 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 600 | 0.040 |
Why?
|
| Transfection | 2 | 2012 | 496 | 0.040 |
Why?
|
| Cell Survival | 2 | 2012 | 818 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2024 | 874 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 396 | 0.040 |
Why?
|
| Casein Kinase II | 1 | 2015 | 15 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 114 | 0.030 |
Why?
|
| Androstenedione | 2 | 2006 | 16 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 27 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 79 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2012 | 15 | 0.030 |
Why?
|
| Serine | 1 | 2012 | 72 | 0.030 |
Why?
|
| Benzylamines | 1 | 2011 | 6 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 90 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 298 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 21 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 480 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 245 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 605 | 0.020 |
Why?
|
| Response Elements | 1 | 2010 | 52 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 430 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 186 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 164 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 114 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 211 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2009 | 61 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 878 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 350 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2008 | 103 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 78 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 109 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 597 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 467 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 1023 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 859 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 580 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 41 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 139 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2006 | 122 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 642 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 391 | 0.020 |
Why?
|
| Choriocarcinoma | 1 | 1998 | 2 | 0.010 |
Why?
|
| Microsomes | 1 | 1998 | 52 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 269 | 0.010 |
Why?
|
| Placenta | 1 | 1998 | 91 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 252 | 0.010 |
Why?
|
| Base Sequence | 1 | 1998 | 932 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1152 | 0.010 |
Why?
|